ID   CHLA-25
AC   CVCL_M152
SY   CHLA25
DR   cancercelllines; CVCL_M152
DR   Cosmic; 2228216
DR   GEO; GSM1676353
DR   GEO; GSM1701683
DR   GEO; GSM5359640
DR   GEO; GSM5359641
DR   GEO; GSM5359642
DR   GEO; GSM5359643
DR   GEO; GSM5359644
DR   GEO; GSM5359645
DR   GEO; GSM5362884
DR   GEO; GSM5362885
DR   GEO; GSM5362886
DR   GEO; GSM5362887
DR   GEO; GSM5362888
DR   GEO; GSM5362889
DR   GEO; GSM5363946
DR   GEO; GSM5363947
DR   GEO; GSM5363948
DR   GEO; GSM5363949
DR   GEO; GSM5363950
DR   Wikidata; Q54812489
RX   DOI=10.5282/edoc.27750;
RX   PubMed=24312454;
RX   PubMed=25010205;
RX   PubMed=26351324;
RX   PubMed=36476851;
WW   Info; ESCLA; -; https://hgserver1.amc.nl/cgi-bin/r2/main.cgi?option=about_dscope
WW   Provider; CCR; -; https://www.cccells.org/PDF_Files/Ewings/CHLA-25%20Cell%20Line%20Data%20Sheet.pdf
WW   Provider; CCR; -; https://www.cccells.org/tables/Ewings.php
CC   Part of: Ewing Sarcoma Cell Line Atlas (ESCLA).
CC   Doubling time: 99 hours (PubMed=24312454).
CC   Sequence variation: Gene fusion; HGNC; HGNC:3446; ERG + HGNC; HGNC:3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG; Note=EWSR1 exon 7 with ERG exon 6 (PubMed=25010205; PubMed=36476851).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=25010205).
CC   Omics: Genomics; ChIP-seq; ERG.
CC   Omics: Genomics; ChIP-seq; H3K27ac.
CC   Omics: Genomics; ChIP-seq; H3K27me3.
CC   Omics: Genomics; ChIP-seq; H3K4me3.
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole genome sequencing.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Proteomics.
CC   Omics: Transcriptomics; RNAseq.
ST   Source(s): COG; PubMed=24312454; PubMed=25010205
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 10,12
ST   D16S539: 11,12
ST   D18S51: 14,17
ST   D19S433: 14
ST   D21S11: 29,32.2
ST   D2S1338: 19,22
ST   D3S1358: 17,18
ST   D5S818: 10
ST   D7S820: 8,10
ST   D8S1179: 13,15
ST   FGA: 24,25
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 15,17
DI   NCIt; C3716; Primitive neuroectodermal tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A444 ! TTC-466
SX   Female
AG   2Y7M
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 10-04-25; Version: 18
//
RX   DOI=10.5282/edoc.27750;
RA   Orth M.F.;
RT   "Systematic multi-omics profiling of Ewing sarcoma cell lines.";
RL   Thesis PhD (2021); Ludwig Maximilians University of Munich; Munich; Germany.
//
RX   PubMed=24312454; DOI=10.1371/journal.pone.0080060; PMCID=PMC3846563;
RA   May W.A., Grigoryan R.S., Keshelava N., Cabral D.J., Christensen L.L.,
RA   Jenabi J., Ji L.-Y., Triche T.J., Lawlor E.R., Reynolds C.P.;
RT   "Characterization and drug resistance patterns of Ewing's sarcoma
RT   family tumor cell lines.";
RL   PLoS ONE 8:e80060.1-e80060.10(2013).
//
RX   PubMed=25010205; DOI=10.1371/journal.pgen.1004475; PMCID=PMC4091782;
RA   Brohl A.S., Solomon D.A., Chang W., Wang J.-J., Song Y., Sindiri S.,
RA   Patidar R., Hurd L., Chen L., Shern J.F., Liao H.-L., Wen X.-Y.,
RA   Gerard J., Kim J.-S., Lopez Guerrero J.A., Machado I., Wai D.H.,
RA   Picci P., Triche T.J., Horvai A.E., Miettinen M.M., Wei J.S.,
RA   Catchpoole D., Llombart-Bosch A., Waldman T.A., Khan J.;
RT   "The genomic landscape of the Ewing sarcoma family of tumors reveals
RT   recurrent STAG2 mutation.";
RL   PLoS Genet. 10:e1004475.1-e1004475.13(2014).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074; PMCID=PMC4636476;
RA   Teicher B.A., Polley E.C., Kunkel M.W., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=36476851; DOI=10.1016/j.celrep.2022.111761; PMCID=PMC10333306;
RA   Orth M.F., Surdez D., Faehling T., Ehlers A.C., Marchetto A.,
RA   Grossetete-Lalami S., Volckmann R., Zwijnenburg D.A., Gerke J.S., Zaidi S.,
RA   Alonso J., Sastre A., Baulande S., Sill M., Cidre-Aranaz F., Ohmura S.,
RA   Kirchner T., Hauck S.M., Reischl E., Gymrek M., Pfister S.M., Strauch K.,
RA   Koster J., Delattre O., Grunewald T.G.P.;
RT   "Systematic multi-omics cell line profiling uncovers principles of
RT   Ewing sarcoma fusion oncogene-mediated gene regulation.";
RL   Cell Rep. 41:111761.1-111761.28(2022).
//